April 24, 2006 -- Progenics Pharma bought out the 50% stake of its partner Cytogen in a joint venture developing in vivo cancer immunotherapies; BioSante Pharma said that BioVant, its nanoparticle-based vaccine adjuvant, increased the effect of an avian flu antigen in mice; VaxGen postponed its discussion of its anthrax vaccine, scheduled for a pre-conference symposium today; Light Sciences Oncology, with a novel device-drug combination for cancer, filed for its IPO; the FDA gave Akorn approval to put its anti-nausea drug back on the market; NeoPharm reported better survival numbers for cintredekin besudotox against brain cancer; and Immunomedics published positive data from a Phase II study of its lupus drug. The Centient Biotech 200™ fell 4 points to 3795.97, a loss of .11%. More details...
